H.C. Wainwright analyst Robert Burns lowered the firm’s price target on SpringWorks Therapeutics to $58 from $66 and keeps a Buy rating on the shares post the Q3 report. The firm is assuming greater operating expenses moving forward and pushed back the initial U.S. launch for nirogacestat in desmoid tumors to Q1 of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SWTX:
- SpringWorks Therapeutics reports Q3 EPS ($1.27), consensus ($1.33)
- SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- SpringWorks Therapeutics to present additional data from Phase 3 DeFi trial
- SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
- SpringWorks Therapeutics to participate in a conference call with JPMorgan